• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glaukos shares tumble despite Q1 beat

May 4, 2017 By Sarah Faulkner

Glaukos logoShares in Glaukos (NYSE:GKOS) fell -10% today after the ophthalmic medtech company beat expectations on Wall Street with its 1st quarter results.

The San Clemente, Calif.-based company posted profits of $878,000, or 2¢ per share, on sales of $35.9 million for the 3 months ended March 31, for bottom-line loss of -2% on sales growth of 55% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 2¢, ahead of consensus on The Street, where analysts were looking for sales of $33.7 million. Compared to Q1 in 2016, earnings per share were down by a penny.

“This marks our 15th consecutive quarter of at least 40% year-over-year net sales growth, demonstrating continued strong demand for our pioneering micro-scale glaucoma products,” president & CEO Thomas Burns said in prepared remarks.  “We are off to a solid start in 2017, focusing our resources and energy on driving U.S. adoption of our flagship iStent Trabecular Micro-Bypass Stent, pursuing regulatory approval of our pipeline technologies and expanding our direct sales operations into targeted international markets.”

Glaukos raised its sales guidance for the full year of 2017, saying it expects to bring in between $162 to $167 million.

GKOS shares were trading at $42.52 apiece today in morning activity, down -10.7%.

Also this week, Glaukos said it finished enrolling patients for the investigational new drug Phase II study of its iDose travoprost intraocular implant in patients with glaucoma.

In the 150-patient trial, the iDose delivery system is designed to continuously elute a special formulation of travopost into the anterior chamber of the eye. The company plans to study 2 models of the iDose system with different travoprost elution rates compared to a topical 0.5% timolol maleate ophthalmic solution.

The trial will assess preliminary safety and efficacy in lowering intraocular pressure in patients with open-angle glaucoma, according to the company.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Glaukos Corp.

IN CASE YOU MISSED IT

  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec
  • Evonik buys polymers business from Durect Corp.
  • New Croatian notified body designated to European MDR

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS